Russell Investments Group
ALLO icon

Russell Investments Group’s Allogene Therapeutics ALLO Stock Holding History

Russell Investments Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$912K Buy
438,409
+256,065
+140% +$562K ﹤0.01% 2502
2026
Q1 		$445K Buy
182,344
+142,303
+355% +$285K ﹤0.01% 2546
2025
Q4 		$54.9K Buy
40,041
+18,197
+83% +$24K ﹤0.01% 3266
2025
Q3 		$27.1K Buy
21,844
+21,650
+11,160% +$25.8K ﹤0.01% 3506
2025
Q2 		$219 Sell
194
-2,371
-92% -$3.15K ﹤0.01% 3786
2025
Q1 		$3.75K Buy
2,565
+1,978
+337% +$3.73K ﹤0.01% 3410
2024
Q4 		$1.25K Buy
+587
New +$1.45K ﹤0.01% 3506
2024
Q3 		– Sell
-80,197
Closed -$187K – 3689
2024
Q2 		$187K Buy
+80,197
New +$237K ﹤0.01% 2492
2022
Q4 		– Sell
-26,668
Closed -$287K – 2891
2022
Q3 		$287K Buy
+26,668
New +$362K ﹤0.01% 2448
2022
Q2 		– Sell
-35,400
Closed -$321K – 2877
2022
Q1 		$321K Buy
+35,400
New +$369K ﹤0.01% 2359
2021
Q4 		– Sell
-7,641
Closed -$196K – 2989
2021
Q3 		$196K Buy
7,641
+6,333
+484% +$150K ﹤0.01% 2777
2021
Q2 		$34K Sell
1,308
-56,521
-98% -$1.61M ﹤0.01% 3159
2021
Q1 		$2.04M Sell
57,829
-11,744
-17% -$396K ﹤0.01% 1868
2020
Q4 		$1.76M Buy
69,573
+41,136
+145% +$1.34M ﹤0.01% 1826
2020
Q3 		$1.07M Buy
28,437
+24,386
+602% +$919K ﹤0.01% 2040
2020
Q2 		$172K Sell
4,051
-7,808
-66% -$282K ﹤0.01% 2748
2020
Q1 		$230K Sell
11,859
-48,209
-80% -$1.15M ﹤0.01% 2492
2019
Q4 		$1.56M Buy
60,068
+23,512
+64% +$648K ﹤0.01% 1874
2019
Q3 		$996K Buy
+36,556
New +$1.04M ﹤0.01% 2003

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Russell Investments Group's ALLO Position: Q2 2026 in Review

Russell Investments Group increased its Allogene Therapeutics (ALLO) stake by 140% in Q2 2026, buying an estimated $562K and bringing the position to 438,409 shares worth $912K. The position accounts for ﹤0.01% of the portfolio, ranked #2502.

Russell Investments Group first reported a position in ALLO in Q3 2019 and has held it in 19 quarters since. The position peaked at $2.04M in Q1 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Russell Investments Group held 438,409 shares of Allogene Therapeutics worth $912K as of Q2 2026.
  • Russell Investments Group bought 256,065 Allogene Therapeutics shares in Q2 2026, an estimated $562K.
  • Allogene Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #2502 holding.
  • Russell Investments Group first reported a position in Allogene Therapeutics in Q3 2019 and has held it in 19 quarters since.
  • Russell Investments Group's Allogene Therapeutics position peaked at $2.04M in Q1 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.